PE20130511A1 - Formulaciones de insulina de accion prolongada - Google Patents
Formulaciones de insulina de accion prolongadaInfo
- Publication number
- PE20130511A1 PE20130511A1 PE2012002170A PE2012002170A PE20130511A1 PE 20130511 A1 PE20130511 A1 PE 20130511A1 PE 2012002170 A PE2012002170 A PE 2012002170A PE 2012002170 A PE2012002170 A PE 2012002170A PE 20130511 A1 PE20130511 A1 PE 20130511A1
- Authority
- PE
- Peru
- Prior art keywords
- long
- acting insulin
- insulin formulations
- insulin
- formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000016261 Long-Acting Insulin Human genes 0.000 title 1
- 108010092217 Long-Acting Insulin Proteins 0.000 title 1
- 229940100066 Long-acting insulin Drugs 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
- 102000004877 Insulin Human genes 0.000 abstract 2
- 108090001061 Insulin Proteins 0.000 abstract 2
- 229940125396 insulin Drugs 0.000 abstract 2
- -1 EXENATIZED Chemical class 0.000 abstract 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA ACUOSA DE ACCION PROLONGADA QUE COMPRENDE: A) DE 200 A 1000 U/ML DE INSULINA GLARGINA QUE ES EQUIMOLAR A 200-1000 UI DE INSULINA HUMANA; B) UN ANALOGO DE EXENDINA-4 TAL COMO EXENATIDA, LIRAGLUTIDA O LIXISENATIDA EN UNA CANTIDAD DE 0,1ug A 10ug POR U DE INSULINA GLARGINA; C) 90 ug/ML DE CINC; D) 2,7 MG/ML DE M-CRESOL; E) 20 ug/ML DE POLISORBATO 20; Y F) 20 MG/ML DE GLICEROL 85%; EN DONDE EL PH DE LA FORMULACION ES DE 3,4 A 4,6. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE DIABETES MELLITUS DE TIPO I Y II
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10305532 | 2010-05-19 | ||
| EP10305780 | 2010-07-13 | ||
| EP11305140 | 2011-02-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20130511A1 true PE20130511A1 (es) | 2013-05-02 |
Family
ID=44148980
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2012002170A PE20130511A1 (es) | 2010-05-19 | 2011-05-18 | Formulaciones de insulina de accion prolongada |
| PE2016000735A PE20160781A1 (es) | 2010-05-19 | 2011-05-18 | Formulaciones de insulina de accion prolongada |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000735A PE20160781A1 (es) | 2010-05-19 | 2011-05-18 | Formulaciones de insulina de accion prolongada |
Country Status (44)
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1969004E (pt) | 2005-12-28 | 2011-11-25 | Novo Nordisk As | Composições que compreendem uma insulina acilada e zinco e método para criar tais composições |
| NZ586590A (en) | 2008-01-09 | 2012-06-29 | Sanofi Aventis Deutschland | Insulin analogues or derivatives having an extremely delayed time-action profile |
| PL3228320T3 (pl) | 2008-10-17 | 2020-06-01 | Sanofi-Aventis Deutschland Gmbh | Kombinacja insuliny i agonisty GLP-1 |
| EP2352513B1 (en) | 2008-10-30 | 2016-09-14 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CN103690958A (zh) * | 2009-07-06 | 2014-04-02 | 赛诺菲-安万特德国有限公司 | 含有甲硫氨酸的水性胰岛素制备物 |
| SI2554183T1 (en) | 2009-11-13 | 2018-08-31 | Sanofi-Aventis Deutschland Gmbh | A pharmaceutical composition comprising the GLP-1 agonist and insulin and methionine |
| DK2498801T3 (en) | 2009-11-13 | 2018-05-07 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION INCLUDING desPro36Exendin-4 (1-39) -Lys6-NH2 AND METHIONIN |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| KR101823320B1 (ko) | 2010-08-30 | 2018-01-31 | 사노피-아벤티스 도이칠란트 게엠베하 | 제２형 진성 당뇨병 치료용 약제를 제조하기 위한 ａｖｅ００１０의 용도 |
| BR112013010345A2 (pt) | 2010-10-27 | 2017-07-25 | Novo Nordisk As | tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção |
| AU2012210481B2 (en) | 2011-01-28 | 2017-05-18 | Sanofi Biotechnology | Pharmaceutical compositions comprising human antibodies to PCSK9 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| FR2984749A1 (fr) * | 2011-12-23 | 2013-06-28 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique |
| JP5950477B2 (ja) | 2011-08-10 | 2016-07-13 | アドシア | 少なくとも１種の基礎インスリンの注射溶液 |
| DK2750699T3 (en) | 2011-08-29 | 2015-10-26 | Sanofi Aventis Deutschland | A pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| TW201333870A (zh) * | 2011-12-21 | 2013-08-16 | 艾登工具股份有限公司 | 決定病人胰島素療法的系統及方法 |
| US9198971B2 (en) | 2012-01-09 | 2015-12-01 | Adocia | Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid |
| FR2985429B1 (fr) * | 2012-01-09 | 2016-07-29 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle |
| FR2985428B1 (fr) * | 2012-01-09 | 2016-05-27 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue |
| WO2014096985A2 (en) * | 2012-12-19 | 2014-06-26 | Wockhardt Limited | A stable aqueous composition comprising human insulin or an analogue or derivative thereof |
| US9588130B2 (en) | 2012-04-18 | 2017-03-07 | Waters Technologies Corporation | Methods for quantifying polypeptides using mass spectrometry |
| AR092862A1 (es) * | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
| FR3001896B1 (fr) | 2013-02-12 | 2015-07-03 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise |
| US20150314003A2 (en) | 2012-08-09 | 2015-11-05 | Adocia | Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| FR3001895B1 (fr) | 2013-02-12 | 2015-07-03 | Adocia | Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes |
| MA38276B1 (fr) | 2012-12-21 | 2018-03-30 | Sanofi Sa | Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif. |
| CN103893744B (zh) * | 2012-12-24 | 2017-12-19 | 杭州九源基因工程有限公司 | 一种治疗糖尿病的药物制剂及其制备方法 |
| MX2015006997A (es) * | 2012-12-26 | 2015-09-23 | Wockhardt Ltd | Composicion farmaceutica. |
| TWI780236B (zh) | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| EP2976096B1 (en) * | 2013-03-20 | 2019-02-27 | Novo Nordisk A/S | Insulin dosing regimen |
| BR112015024659A8 (pt) * | 2013-04-03 | 2019-12-17 | Sanofi Sa | formulação farmacêutica aquosa, seu uso, método de tratamento de diabetes mellitus e artigo de fabricação |
| US20220202711A1 (en) * | 2013-04-03 | 2022-06-30 | Sanofi | Treatment of Diabetes Mellitus by Long-Acting Formulations of Insulins |
| WO2014177623A1 (en) | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
| US20140371141A1 (en) * | 2013-06-17 | 2014-12-18 | Sanofi-Aventis Deutschland Gmbh | Insulin glargine/lixisenatide fixed ratio formulation |
| CN104587455A (zh) * | 2013-10-31 | 2015-05-06 | 江苏万邦生化医药股份有限公司 | 一种胰岛素制剂 |
| EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| WO2015086731A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| KR20160104726A (ko) | 2014-01-09 | 2016-09-05 | 사노피 | 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 무글리세롤 약제학적 제형 |
| CA2932873A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| WO2015104314A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| CN103830189A (zh) * | 2014-03-04 | 2014-06-04 | 山东新时代药业有限公司 | 一种重组甘精胰岛素制剂及其制备方法 |
| JP2017515797A (ja) | 2014-04-04 | 2017-06-15 | サノフイ | 糖尿病、肥満、脂質異常症および関連障害の治療のためのｇｐｒ１１９モジュレーターとしての置換インダノン化合物 |
| TW201623286A (zh) | 2014-04-04 | 2016-07-01 | 賽諾菲公司 | 作為ｇｐｒ１１９調控劑用於治療糖尿病、肥胖、血脂異常及相關病症之異吲哚啉酮化合物 |
| AR099936A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| WO2016001862A1 (en) | 2014-07-04 | 2016-01-07 | Wockhardt Limited | Extended release formulations of insulins |
| KR20230074283A (ko) | 2014-07-16 | 2023-05-26 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
| TN2017000235A1 (en) | 2014-12-12 | 2018-10-19 | Sanofi Aventis Deutschland | Insulin glargine/lixisenatide fixed ratio formulation |
| CN104688678B (zh) * | 2015-02-05 | 2017-11-17 | 通化东宝药业股份有限公司 | 一种甘精胰岛素注射液的制备方法及其制备的甘精胰岛素注射液 |
| CN104688677B (zh) * | 2015-02-05 | 2018-02-09 | 通化东宝药业股份有限公司 | 一种稳定的甘精胰岛素注射液及其制备方法 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
| JP2018523684A (ja) | 2015-08-18 | 2018-08-23 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体 |
| EA039114B1 (ru) * | 2015-11-10 | 2021-12-06 | Санофи-Авентис Дойчланд Гмбх | Применение композиции с постоянным соотношением инсулин гларгин/ликсисенатид для лечения сахарного диабета 2 типа |
| TW201731867A (zh) | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| CN105597087B (zh) * | 2016-01-06 | 2019-04-26 | 山东新时代药业有限公司 | 一种甘精胰岛素注射液及其制备方法 |
| GB201607918D0 (en) | 2016-05-06 | 2016-06-22 | Arecor Ltd | Novel formulations |
| WO2018055539A1 (en) | 2016-09-22 | 2018-03-29 | Wockhardt Limited | Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue |
| AR110299A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Conjugados que comprenden un agonista dual de glp-1 / glucagón, un conector y ácido hialurónico |
| AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
| AR110300A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| AU2017382038A1 (en) | 2016-12-22 | 2019-08-08 | Sanofi | FGF21 compound / GLP-1R agonist combinations with optimized activity ratio |
| US20190031774A1 (en) | 2017-06-09 | 2019-01-31 | Sanofi Biotechnology | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
| ES2969277T3 (es) * | 2017-07-27 | 2024-05-17 | Adocia | Composiciones en forma de una solución acuosa inyectable que comprenden al menos insulina humana A21G y un supresor de glucagón con acción prandial |
| UY38249A (es) | 2018-05-30 | 2019-12-31 | Sanofi Sa | Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico |
| JP2021528422A (ja) | 2018-06-21 | 2021-10-21 | サノフイＳａｎｏｆｉ | 最適化された活性比を有するｆｇｆ２１化合物／ｇｌｐ−１ｒアゴニストの組合せ |
| WO2019243628A1 (fr) | 2018-06-22 | 2019-12-26 | Adocia | Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US20220233784A1 (en) | 2019-05-29 | 2022-07-28 | Sanofi | Drug delivery device |
| JP7518149B2 (ja) | 2019-07-12 | 2024-07-17 | ノヴォ ノルディスク アー／エス | 高濃度インスリン製剤 |
| WO2021113136A1 (en) * | 2019-12-06 | 2021-06-10 | Dr. Mary Morris & Associates, Llc | Methods and compositions for the treatment and prevention of type 1 diabetes |
| BR112022023609A2 (pt) * | 2020-05-22 | 2023-02-07 | Hanmi Pharm Ind Co Ltd | Formulação líquida de conjugado de ação prolongada de agonista trigonal de glucagon, glp-1 e gip |
| US20230250147A1 (en) | 2020-07-02 | 2023-08-10 | Sanofi | Glp-1r agonistic peptides with reduced activity |
| US20230265152A1 (en) | 2020-07-02 | 2023-08-24 | Sanofi | Glp-1r agonist / fgf21 fusion proteins |
| US20230302095A1 (en) * | 2020-08-14 | 2023-09-28 | Kyon Biotech Ag | Increasing the efficacy of biological therapeutic molecules |
| JP2023544832A (ja) * | 2020-10-08 | 2023-10-25 | ドクター メアリー モリス アンド アソシエイツ リミテッド ライアビリティ カンパニー | １型糖尿病の治療および予防のための方法および組成物 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4960702A (en) | 1985-09-06 | 1990-10-02 | Codon | Methods for recovery of tissue plasminogen activator |
| PH23446A (en) | 1986-10-20 | 1989-08-07 | Novo Industri As | Peptide preparations |
| DE3837825A1 (de) * | 1988-11-08 | 1990-05-10 | Hoechst Ag | Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung |
| CH682806A5 (de) * | 1992-02-21 | 1993-11-30 | Medimpex Ets | Injektionsgerät. |
| CH682805A5 (de) * | 1992-02-24 | 1993-11-30 | Medimpex Ets | Anzeigeeinrichtung für ein Injektionsgerät. |
| CA2183577C (en) | 1994-03-07 | 2007-10-30 | John S. Patton | Methods and compositions for pulmonary delivery of insulin |
| AR002976A1 (es) * | 1995-03-31 | 1998-05-27 | Lilly Co Eli | Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas |
| ZA984697B (en) | 1997-06-13 | 1999-12-01 | Lilly Co Eli | Stable insulin formulations. |
| EA200000453A1 (ru) | 1997-10-24 | 2000-10-30 | Эли Лилли Энд Компани | Композиции нерастворимого инсулина |
| US6978471B1 (en) | 1999-05-25 | 2005-12-20 | Thomson Licensing S.A. | System for acquiring and processing broadcast programs and program guide data |
| US6528486B1 (en) | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| US7022674B2 (en) | 1999-12-16 | 2006-04-04 | Eli Lilly And Company | Polypeptide compositions with improved stability |
| DK1326630T3 (da) | 2000-09-18 | 2008-09-15 | Sanos Bioscience As | Anvendelse af GLP-2-peptider |
| AU2002248464A1 (en) | 2001-02-21 | 2002-09-12 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| US20030026872A1 (en) | 2001-05-11 | 2003-02-06 | The Procter & Gamble Co. | Compositions having enhanced aqueous solubility and methods of their preparation |
| FR2827604B1 (fr) | 2001-07-17 | 2003-09-19 | Sanofi Synthelabo | Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant |
| JP2005508895A (ja) * | 2001-08-28 | 2005-04-07 | イーライ・リリー・アンド・カンパニー | Ｇｌｐ−１および基礎インスリンの予備混合物 |
| US20100069293A1 (en) | 2002-02-27 | 2010-03-18 | Pharmain Corporation | Polymeric carrier compositions for delivery of active agents, methods of making and using the same |
| US7115563B2 (en) | 2002-05-29 | 2006-10-03 | Insignion Holding Limited | Composition and its therapeutic use |
| DE10227232A1 (de) * | 2002-06-18 | 2004-01-15 | Aventis Pharma Deutschland Gmbh | Saure Insulinzubereitungen mit verbesserter Stabilität |
| EP2028192A1 (en) | 2002-07-04 | 2009-02-25 | Zealand Pharma A/S | GLP-1 and methods for treating diabetes |
| DE10235168A1 (de) | 2002-08-01 | 2004-02-12 | Aventis Pharma Deutschland Gmbh | Verfahren zur Reinigung von Preproinsulin |
| GB0309154D0 (en) | 2003-01-14 | 2003-05-28 | Aventis Pharma Inc | Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia |
| EP1585453A4 (en) | 2003-01-21 | 2007-05-02 | Ortho Tain Inc | DENTAL APPARATUS, SYSTEM AND METHOD FOR REDUCING PATIENT COOPERATION QUANTITY TO TREAT DENTAL MALOCCLUSION USING THE DENTAL DEVICE |
| GB0304822D0 (en) * | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
| AR046485A1 (es) | 2003-03-04 | 2005-12-14 | Technology Dev Company Ltd | Sistema de administracion para drogas y terapia celular |
| WO2005020927A2 (en) | 2003-08-29 | 2005-03-10 | Centocor, Inc. | Method of promoting graft survival with anti-tissue factor antibodies |
| DE602004029496D1 (de) * | 2003-12-22 | 2010-11-18 | Novo Nordisk As | Offbehälter zur lagerung von pharmazeutischen flüssigkeiten |
| EP1701714A2 (en) | 2004-01-07 | 2006-09-20 | Nektar Therapeutics | Improved sustained release compositions for pulmonary administration of insulin |
| WO2005097175A2 (en) | 2004-03-31 | 2005-10-20 | Centocor, Inc. | Human glp-1 mimetibodies, compositions, methods and uses |
| CA2592065A1 (en) | 2004-12-22 | 2007-04-26 | Centocor, Inc. | Glp-1 agonists, compositions, methods and uses |
| US7879361B2 (en) | 2005-01-04 | 2011-02-01 | Gp Medical, Inc. | Nanoparticles for drug delivery |
| US20070078510A1 (en) | 2005-09-26 | 2007-04-05 | Ryan Timothy R | Prosthetic cardiac and venous valves |
| US8084420B2 (en) | 2005-09-29 | 2011-12-27 | Biodel Inc. | Rapid acting and long acting insulin combination formulations |
| US8530447B2 (en) * | 2005-10-24 | 2013-09-10 | Nestec S.A. | Dietary fiber formulation and method of administration |
| EA200800979A1 (ru) | 2005-11-30 | 2008-10-30 | Дженерекс Фармасьютикалз Инк. | Перорально абсорбируемая фармацевтическая композиция и способ введения |
| US20100029558A1 (en) | 2005-12-06 | 2010-02-04 | Bristow Cynthia L | Alpha1 proteinase inhibitor peptides methods and use |
| CN101454019A (zh) * | 2006-04-12 | 2009-06-10 | 百达尔公司 | 速效和长效胰岛素联合制剂 |
| US20090099064A1 (en) | 2006-06-08 | 2009-04-16 | Diabecore Medical Inc., | Derivatized insulin oligomers |
| DE102006031962A1 (de) * | 2006-07-11 | 2008-01-17 | Sanofi-Aventis Deutschland Gmbh | Amidiertes Insulin Glargin |
| EP2076242B8 (en) * | 2006-07-27 | 2013-02-20 | Nektar Therapeutics | Aerosolizable formulation comprising insulin for pulmonary delivery |
| WO2008124522A2 (en) | 2007-04-04 | 2008-10-16 | Biodel, Inc. | Amylin formulations |
| EP2185689A2 (en) | 2007-08-09 | 2010-05-19 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
| US8575096B2 (en) | 2007-08-13 | 2013-11-05 | Novo Nordisk A/S | Rapid acting insulin analogues |
| EP2597103B1 (en) * | 2007-11-16 | 2016-11-02 | Novo Nordisk A/S | Stable pharmaceutical compositions comprising liraglutide and degludec |
| US20090175840A1 (en) * | 2008-01-04 | 2009-07-09 | Biodel, Inc. | Insulin formulations for insulin release as a function of tissue glucose levels |
| MX2010009033A (es) | 2008-02-19 | 2010-12-21 | Biocon Ltd | Un metodo para obtener insulinas heterologas purificadas expresadas en levadura. |
| US8329419B2 (en) | 2008-05-23 | 2012-12-11 | Amylin Pharmaceuticals, Llc | GLP-1 receptor agonist bioassays |
| TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| US20100069292A1 (en) | 2008-09-02 | 2010-03-18 | Biodel, Inc. | Insulin with a basal release profile |
| DE102008053048A1 (de) | 2008-10-24 | 2010-04-29 | Sanofi-Aventis Deutschland Gmbh | Kombination von einem Insulin und einem GLP-1-Agonisten |
| PL3228320T3 (pl) | 2008-10-17 | 2020-06-01 | Sanofi-Aventis Deutschland Gmbh | Kombinacja insuliny i agonisty GLP-1 |
| EP2352513B1 (en) | 2008-10-30 | 2016-09-14 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
| JP2012517977A (ja) | 2009-02-13 | 2012-08-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬 |
| US8709400B2 (en) | 2009-07-27 | 2014-04-29 | Washington University | Inducement of organogenetic tolerance for pancreatic xenotransplant |
| WO2011012719A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Long acting insulin composition |
| PL2329848T5 (pl) | 2009-11-13 | 2019-12-31 | Sanofi-Aventis Deutschland Gmbh | Liksysenatyd z insuliną glargine i metforminą jako terapia skojarzona do leczenia cukrzycy typu 2 |
| DK2498801T3 (en) | 2009-11-13 | 2018-05-07 | Sanofi Aventis Deutschland | PHARMACEUTICAL COMPOSITION INCLUDING desPro36Exendin-4 (1-39) -Lys6-NH2 AND METHIONIN |
| SI2554183T1 (en) | 2009-11-13 | 2018-08-31 | Sanofi-Aventis Deutschland Gmbh | A pharmaceutical composition comprising the GLP-1 agonist and insulin and methionine |
| US20110118178A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin |
| US20110118180A1 (en) | 2009-11-13 | 2011-05-19 | Sanofi-Aventis Deutschland Gmbh | Method of treatment of diabetes type 2 comprising add-on therapy to metformin |
| CN102933200B (zh) | 2009-12-18 | 2015-11-25 | 莱迪杜德制药公司 | 包含磷脂的单相凝胶组合物 |
| MX2012009618A (es) | 2010-02-22 | 2013-02-26 | Univ Case Western Reserve | Preperaciones de analogo de insulina de larga accion en formas solubles y cristalinas. |
| AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
| TW201141513A (en) | 2010-04-14 | 2011-12-01 | Sanofi Aventis | Insulin-siRNA conjugates |
| US8637458B2 (en) | 2010-05-12 | 2014-01-28 | Biodel Inc. | Insulin with a stable basal release profile |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| WO2011144674A2 (en) | 2010-05-20 | 2011-11-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD |
| EP2389945A1 (en) | 2010-05-28 | 2011-11-30 | Sanofi-Aventis Deutschland GmbH | Pharmaceutical composition comprising AVE0010 and insulin glargine |
| WO2011160066A1 (en) | 2010-06-17 | 2011-12-22 | Regents Of The University Of Minnesota | Production of insulin producing cells |
| US8532933B2 (en) | 2010-06-18 | 2013-09-10 | Roche Diagnostics Operations, Inc. | Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers |
| KR101823320B1 (ko) | 2010-08-30 | 2018-01-31 | 사노피-아벤티스 도이칠란트 게엠베하 | 제２형 진성 당뇨병 치료용 약제를 제조하기 위한 ａｖｅ００１０의 용도 |
| CA2815419A1 (en) | 2010-10-27 | 2012-05-03 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections administered with varying injection intervals |
| WO2012065996A1 (en) | 2010-11-15 | 2012-05-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN |
| WO2012066086A1 (en) | 2010-11-17 | 2012-05-24 | Sanofi-Aventis Deutschland Gmbh | PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN |
| TW201236692A (en) | 2011-02-02 | 2012-09-16 | Sanofi Aventis Deutschland | Prevention of hypoglycaemia in diabetes mellitus type 2 patients |
| PL3556774T3 (pl) | 2011-03-11 | 2024-07-01 | Beth Israel Deaconess Medical Center Inc. | Przeciwciała anty-cd40 i ich zastosowania |
| WO2013050378A1 (en) | 2011-10-04 | 2013-04-11 | Sanofi-Aventis Deutschland Gmbh | Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract |
-
2011
- 2011-05-16 AU AU2011202239A patent/AU2011202239C1/en active Active
- 2011-05-17 DK DK11166415.7T patent/DK2387989T3/da active
- 2011-05-17 EP EP18161680.6A patent/EP3424491A1/en not_active Withdrawn
- 2011-05-17 EP EP23157670.3A patent/EP4218723A3/en not_active Withdrawn
- 2011-05-17 LT LTEP14166877.2T patent/LT2781212T/lt unknown
- 2011-05-17 RS RSP20140522 patent/RS53559B1/sr unknown
- 2011-05-17 PT PT111664157T patent/PT2387989E/pt unknown
- 2011-05-17 ES ES11166415.7T patent/ES2509943T3/es active Active
- 2011-05-17 JP JP2011110037A patent/JP5269945B2/ja active Active
- 2011-05-17 SI SI201130267T patent/SI2387989T1/sl unknown
- 2011-05-17 TW TW100117134A patent/TWI469787B/zh active
- 2011-05-17 HU HUE14166877A patent/HUE039355T2/hu unknown
- 2011-05-17 TW TW103110412A patent/TWI496580B/zh active
- 2011-05-17 PL PL20199940.6T patent/PL3824876T3/pl unknown
- 2011-05-17 SI SI201131519T patent/SI2781212T1/en unknown
- 2011-05-17 EP EP20199940.6A patent/EP3824876B8/en active Active
- 2011-05-17 PL PL11166415T patent/PL2387989T3/pl unknown
- 2011-05-17 EP EP14166877.2A patent/EP2781212B1/en active Active
- 2011-05-17 ES ES20199940T patent/ES2945208T3/es active Active
- 2011-05-17 PL PL14166877T patent/PL2781212T3/pl unknown
- 2011-05-17 ES ES14166877.2T patent/ES2676401T3/es active Active
- 2011-05-17 EP EP11166415.7A patent/EP2387989B1/en active Active
- 2011-05-17 EP EP19184732.6A patent/EP3636250A1/en not_active Withdrawn
- 2011-05-17 UY UY0001033391A patent/UY33391A/es active IP Right Grant
- 2011-05-17 AR ARP110101688A patent/AR081200A1/es not_active Application Discontinuation
- 2011-05-17 DK DK14166877.2T patent/DK2781212T3/en active
- 2011-05-17 TW TW106106304A patent/TW201735941A/zh unknown
- 2011-05-17 JO JO2011163A patent/JO2944B1/en active
- 2011-05-17 TR TR2018/09475T patent/TR201809475T4/tr unknown
- 2011-05-17 TW TW104116749A patent/TWI605825B/zh active
- 2011-05-17 PT PT141668772T patent/PT2781212T/pt unknown
- 2011-05-18 ES ES11720115T patent/ES2690302T5/es active Active
- 2011-05-18 PH PH1/2012/501895A patent/PH12012501895A1/en unknown
- 2011-05-18 BR BR112012029131-9A patent/BR112012029131B1/pt active IP Right Grant
- 2011-05-18 KR KR1020177016698A patent/KR20170072960A/ko not_active Ceased
- 2011-05-18 HR HRP20181028TT patent/HRP20181028T2/hr unknown
- 2011-05-18 DK DK11720115.2T patent/DK2571517T4/da active
- 2011-05-18 MX MX2012011278A patent/MX343489B/es active IP Right Grant
- 2011-05-18 CA CA2792669A patent/CA2792669C/en active Active
- 2011-05-18 WO PCT/EP2011/058079 patent/WO2011144673A2/en not_active Ceased
- 2011-05-18 MY MYPI2012004140A patent/MY156188A/en unknown
- 2011-05-18 KR KR1020127026802A patent/KR101486743B1/ko active Active
- 2011-05-18 PT PT117201152T patent/PT2571517T/pt unknown
- 2011-05-18 EP EP19174460.6A patent/EP3607935A1/en not_active Withdrawn
- 2011-05-18 SG SG10201510406YA patent/SG10201510406YA/en unknown
- 2011-05-18 RU RU2011119988/15A patent/RU2564104C2/ru active
- 2011-05-18 FI FIEP11720115.2T patent/FI2571517T4/fi active
- 2011-05-18 SI SI201131518T patent/SI2571517T2/sl unknown
- 2011-05-18 MA MA35358A patent/MA34224B1/fr unknown
- 2011-05-18 EP EP18155758.8A patent/EP3400931A1/en not_active Withdrawn
- 2011-05-18 PL PL11720115.2T patent/PL2571517T5/pl unknown
- 2011-05-18 NZ NZ602541A patent/NZ602541A/xx unknown
- 2011-05-18 BR BR122019006884-4A patent/BR122019006884B1/pt active IP Right Grant
- 2011-05-18 EP EP11720115.2A patent/EP2571517B9/en active Active
- 2011-05-18 MX MX2019003693A patent/MX389052B/es unknown
- 2011-05-18 KR KR1020187021814A patent/KR101989343B1/ko active Active
- 2011-05-18 PE PE2012002170A patent/PE20130511A1/es active IP Right Grant
- 2011-05-18 KR KR1020147023925A patent/KR101913672B1/ko active Active
- 2011-05-18 SG SG2012084208A patent/SG185593A1/en unknown
- 2011-05-18 US US13/110,568 patent/US20110301081A1/en not_active Abandoned
- 2011-05-18 TR TR2018/09514T patent/TR201809514T4/tr unknown
- 2011-05-18 HU HUE11720115A patent/HUE039354T2/hu unknown
- 2011-05-18 LT LTEP11720115.2T patent/LT2571517T/lt unknown
- 2011-05-18 PE PE2016000735A patent/PE20160781A1/es unknown
- 2011-05-19 CN CN201710324824.8A patent/CN107583038A/zh active Pending
- 2011-05-19 CN CN201410818149.0A patent/CN104622788A/zh active Pending
- 2011-05-19 CN CN201710249012.1A patent/CN107583037A/zh active Pending
- 2011-05-19 CN CN201410220537.9A patent/CN103948913A/zh active Pending
- 2011-05-19 CN CN2011102251176A patent/CN102319422A/zh not_active Withdrawn
- 2011-12-02 US US13/310,118 patent/US20120122774A1/en not_active Abandoned
-
2012
- 2012-03-13 HK HK15111312.1A patent/HK1210435A1/xx unknown
- 2012-03-13 HK HK14111946.6A patent/HK1198428A1/xx unknown
- 2012-03-13 HK HK18108478.4A patent/HK1248592A1/zh unknown
- 2012-03-13 HK HK18108479.3A patent/HK1248593A1/zh unknown
- 2012-09-13 IL IL221964A patent/IL221964A/en active IP Right Grant
- 2012-09-18 ZA ZA2012/06998A patent/ZA201206998B/en unknown
- 2012-10-01 TN TNP2012000478A patent/TN2012000478A1/en unknown
- 2012-10-02 DO DO2012000261A patent/DOP2012000261A/es unknown
- 2012-10-03 NI NI201200152A patent/NI201200152A/es unknown
- 2012-10-23 GT GT201200287A patent/GT201200287A/es unknown
- 2012-11-08 CO CO12201607A patent/CO6640217A2/es unknown
- 2012-11-13 CR CR20120578A patent/CR20120578A/es unknown
- 2012-11-15 CL CL2012003197A patent/CL2012003197A1/es unknown
- 2012-11-16 EC ECSP12012298 patent/ECSP12012298A/es unknown
-
2013
- 2013-05-07 JP JP2013097274A patent/JP2013147509A/ja not_active Withdrawn
-
2014
- 2014-03-20 US US14/220,562 patent/US9345750B2/en active Active
- 2014-09-11 HR HRP20140860AT patent/HRP20140860T1/hr unknown
- 2014-10-15 CY CY20141100842T patent/CY1115649T1/el unknown
-
2015
- 2015-02-17 US US14/624,575 patent/US20150164999A1/en not_active Abandoned
- 2015-06-03 JP JP2015112917A patent/JP6333775B2/ja active Active
- 2015-06-19 PH PH12015501421A patent/PH12015501421B1/en unknown
- 2015-08-06 RU RU2015132860A patent/RU2642662C2/ru active
- 2015-10-07 JO JOP/2015/0245A patent/JOP20150245B1/ar active
-
2016
- 2016-04-20 US US15/134,152 patent/US20160228516A1/en not_active Abandoned
- 2016-05-23 US US15/162,563 patent/US20160339084A1/en not_active Abandoned
-
2017
- 2017-03-21 IL IL251318A patent/IL251318B/en active IP Right Grant
- 2017-12-13 JP JP2017238185A patent/JP2018044003A/ja active Pending
- 2017-12-27 RU RU2017146048A patent/RU2017146048A/ru unknown
-
2018
- 2018-07-04 CY CY181100700T patent/CY1121042T1/el unknown
- 2018-07-04 HR HRP20181026TT patent/HRP20181026T1/hr unknown
- 2018-07-04 CY CY20181100701T patent/CY1120407T1/el unknown
- 2018-08-21 US US16/108,064 patent/US20190046616A1/en not_active Abandoned
-
2019
- 2019-03-11 PH PH12019500517A patent/PH12019500517A1/en unknown
- 2019-03-28 US US16/368,201 patent/US20190388511A1/en not_active Abandoned
- 2019-09-17 US US16/572,850 patent/US20200215163A1/en not_active Abandoned
- 2019-12-13 JP JP2019224977A patent/JP2020040990A/ja active Pending
-
2020
- 2020-05-13 US US15/930,643 patent/US20200384087A1/en not_active Abandoned
-
2021
- 2021-02-16 US US17/176,442 patent/US20210308225A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20130511A1 (es) | Formulaciones de insulina de accion prolongada | |
| BR112012017054A2 (pt) | "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica" | |
| PE20161408A1 (es) | Composiciones de insulina de rapida accion | |
| NI201200013A (es) | Composición de insulina de acción prolongada | |
| WO2011075393A3 (en) | Glucagon/glp-1 receptor co-agonists | |
| CL2011001082A1 (es) | Compuestos derivados de amino-tetrahidropiranos sustituidos con heterociclos, composicion farmaceutica; y uso en el tratamiento de una afeccion seleccionada de resistencia a la insulina, hiperglicemia y diabetes de tipo 2. | |
| PH12015501931B1 (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
| ES2445846R1 (es) | Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos | |
| PE20131034A1 (es) | El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isomero posicional | |
| TN2012000516A1 (en) | Stable ready to use injectable paracetamol formulation | |
| AU2010353685A8 (en) | Novel glucagon like peptide analogs, composition, and method of use | |
| IN2012DN00977A (es) | ||
| PE20160847A1 (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
| NZ603783A (en) | Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant | |
| PE20160848A1 (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa | |
| GR20100100508A (el) | Ποσιμα φαρμακευτικα διαλυματα για τη θεραπεια του υποθυρεοειδισμου | |
| CO6470880A2 (es) | Soluciones para infusión e inyección de diacetato de ipamorelina. | |
| TR201105424A2 (tr) | Çinko etken maddeli bir farmasötik formülasyon. | |
| MX385095B (es) | Composiciones farmaceuticas orales para uso en dislipidemias. | |
| UA92646C2 (ru) | применение производных 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с актопротекторным действием | |
| UA110329C2 (en) | Conjugates of fatty acids and niacin and their use | |
| UA59914U (ru) | Фармацевтическая композиция анксиолитического действия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |